Leachim

Travoprost, the active ingredient in Leachim, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It lowers intra‑ocular pressure and is indicated for patients with open‑angle glaucoma or ocular hypertension. GNH USA supplies Leachim as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Leachim, a prostaglandin analog, is employed to manage conditions that involve elevated intra‑ocular pressure. - Open‑angle glaucoma: reduces intra‑ocular pressure to slow disease progression. - Ocular hypertension: lowers eye pressure to prevent development of glaucoma. - Secondary glaucoma: helps control pressure when caused by other ocular disorders.

Travoprost may cause a range of ocular and systemic reactions.

Common Side Effects: - Eye redness: mild conjunctival hyperemia. - Eye irritation: transient burning or stinging on instillation. - Increased eyelash growth: longer, thicker lashes. - Iris darkening: gradual hyperpigmentation of the iris.

Serious or Rare Side Effects: - Allergic reaction: swelling, rash, or severe eye inflammation. - Eye infection: signs of bacterial or fungal keratitis. - Severe eye pain: may indicate acute angle‑closure glaucoma. - Vision loss: sudden decrease in visual acuity. - Macular edema: rare swelling of the central retina.

Before using Leachim, consider the following safety measures. - Pregnancy: safety not established; avoid unless clearly needed. - Breastfeeding: unknown excretion; weigh potential risks and benefits. - Active ocular inflammation: contraindicated until inflammation resolves. - Monitoring: regular intra‑ocular pressure checks are essential. - Drug interactions: avoid concurrent use of other prostaglandin analog eye drops. - Store at room temperature: keep in original container, protect from moisture and light.

Travoprost can interact with other ophthalmic agents.

Major Interactions (Avoid): - Concurrent prostaglandin analog eye drops: may increase risk of ocular irritation. - Systemic carbonic anhydrase inhibitors: can blunt intra‑ocular pressure‑lowering effect.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory eye drops: may enhance local inflammation. - Beta‑blocker eye drops: additive pressure‑lowering effect, monitor pressure closely. - Anticholinergic agents: potential for reduced aqueous outflow, observe response.